Shandong Keyuan Pharmaceutical Co., Ltd. (SHE:301281)
45.30
+2.55 (5.96%)
At close: Feb 27, 2026
SHE:301281 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Net Income | 52.06 | 60.27 | 77.04 | 91.28 | 78.17 | 68.65 |
Depreciation & Amortization | 43.3 | 43.3 | 48.95 | 33.63 | 26.86 | 25.35 |
Other Amortization | 3.94 | 3.94 | 1.64 | 1.69 | 1.59 | 1.34 |
Loss (Gain) From Sale of Assets | -0.08 | -0.08 | -0.35 | -0.37 | 0.04 | 0.09 |
Asset Writedown & Restructuring Costs | 0.92 | 0.92 | 0.3 | - | - | - |
Loss (Gain) From Sale of Investments | -12.94 | -12.94 | -12.74 | - | - | - |
Provision & Write-off of Bad Debts | 0.29 | 0.29 | 0.31 | 0.84 | 0.11 | -0.92 |
Other Operating Activities | 19.68 | 8.1 | 2.66 | 2.43 | 0.09 | 3.42 |
Change in Accounts Receivable | -162.93 | -162.93 | -18.88 | -43.02 | -42.78 | 23.64 |
Change in Inventory | -28.47 | -28.47 | -42.79 | 16.07 | -16.2 | -12.3 |
Change in Accounts Payable | 26.68 | 26.68 | -20.28 | 6.28 | -5.76 | -4.6 |
Change in Other Net Operating Assets | - | - | - | - | 8.88 | - |
Operating Cash Flow | -57.15 | -60.52 | 37.03 | 115.86 | 52.02 | 105.16 |
Operating Cash Flow Growth | - | - | -68.04% | 122.71% | -50.53% | - |
Capital Expenditures | -190.93 | -296.38 | -70.15 | -31.11 | -20.19 | -7.13 |
Sale of Property, Plant & Equipment | 0.2 | 0.1 | 0.2 | 0.4 | 0.29 | 0.39 |
Cash Acquisitions | - | -1.66 | - | - | - | - |
Investment in Securities | -102.58 | 105.22 | -538.47 | - | - | - |
Other Investing Activities | 25.76 | 5.15 | 6.3 | - | - | -0 |
Investing Cash Flow | -267.54 | -187.58 | -602.13 | -30.71 | -19.9 | -6.74 |
Long-Term Debt Issued | - | 45.62 | - | - | - | - |
Total Debt Issued | 101.02 | 45.62 | - | - | - | - |
Long-Term Debt Repaid | - | - | - | - | - | -88.93 |
Total Debt Repaid | -3.48 | - | - | - | - | -88.93 |
Net Debt Issued (Repaid) | 97.54 | 45.62 | - | - | - | -88.93 |
Issuance of Common Stock | - | - | 782.94 | - | - | - |
Common Dividends Paid | -24.02 | -32.56 | -30.94 | - | - | -1.97 |
Dividends Paid | -24.02 | -32.56 | -30.94 | - | - | -1.97 |
Other Financing Activities | 1.01 | 2.01 | -12.2 | -1.81 | -3.87 | -0 |
Financing Cash Flow | 74.53 | 15.07 | 739.81 | -1.81 | -3.87 | -90.91 |
Foreign Exchange Rate Adjustments | 0.69 | 0.59 | 0.52 | 0.28 | -0.11 | 0.01 |
Miscellaneous Cash Flow Adjustments | - | - | - | - | - | 0 |
Net Cash Flow | -249.47 | -232.44 | 175.23 | 83.63 | 28.13 | 7.53 |
Free Cash Flow | -248.07 | -356.9 | -33.12 | 84.75 | 31.83 | 98.04 |
Free Cash Flow Growth | - | - | - | 166.28% | -67.53% | - |
Free Cash Flow Margin | -56.96% | -76.96% | -7.40% | 19.14% | 7.56% | 26.71% |
Free Cash Flow Per Share | -2.31 | -3.32 | -0.33 | 1.04 | 0.39 | 1.20 |
Cash Income Tax Paid | 12.44 | 19.13 | 25.19 | 24.79 | 27.67 | 37.08 |
Levered Free Cash Flow | -228.61 | -280.59 | -39.21 | 60.98 | 81.63 | 74.71 |
Unlevered Free Cash Flow | -228.57 | -280.57 | -39.21 | 60.98 | 81.63 | 75.86 |
Change in Working Capital | -164.33 | -164.33 | -80.77 | -13.65 | -54.84 | 7.22 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.